Abstract
Cemiplimab (Libtayo(R)) is an antibody immunotherapy that stimulates an anti-cancer response via programmed cell death protein-1 (PD-1) blockade. It i......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
